Nie S Q, Kwan C Y, Epand R M
Department of Biomedical Sciences, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada.
Eur J Pharmacol. 1993 Jan 4;244(1):15-9. doi: 10.1016/0922-4106(93)90054-d.
We have previously demonstrated that several structurally similar pyrazine derivatives, tetramethylpyrazine (TMP), triethylpyrazine (3EP) and tetraethylpyrazine (TEP) consistently inhibited a wide spectrum of plasmalemma-associated biological activities of vascular smooth muscles in contractility and radioligand binding studies in the following order of increasing potency, TMP < 3EP < TEP. We speculated that these pyrazine derivatives elicit multiple effects in the above order of potency by affecting, at least in part, the bulk physical properties of the lipid bilayers in the cell membrane. This hypothesis was tested in the current study using plasmalemma-enriched microsomes isolated from dog aortic smooth muscle using two different biophysical techniques: fluorescence polarization and electron spin resonance. The calculated membrane fluidity values obtained as a function of temperature by both methods are consistent with the above order of potency. The amount of incorporation of these pyrazine derivatives into the vascular smooth muscle membranes also increased with the increasing hydrophobicity of these drugs, i.e., TMP < 3EP < TEP. Our results are consistent with the contention that these pyrazine derivatives not only interact with receptor protein molecules in the biological membranes, but also modulate these receptor properties via their interaction with the lipid bilayer altering the membrane microviscosity.
我们之前已经证明,几种结构相似的吡嗪衍生物,即川芎嗪(TMP)、三乙基吡嗪(3EP)和四乙基吡嗪(TEP),在收缩性和放射性配体结合研究中,始终能抑制血管平滑肌多种与质膜相关的生物活性,其效力顺序为TMP < 3EP < TEP,效力逐渐增强。我们推测,这些吡嗪衍生物至少部分通过影响细胞膜脂质双层的整体物理性质,以上述效力顺序产生多种效应。在本研究中,我们使用从犬主动脉平滑肌分离的富含质膜的微粒体,采用两种不同的生物物理技术(荧光偏振和电子自旋共振)对这一假设进行了验证。通过这两种方法获得的作为温度函数的计算膜流动性值与上述效力顺序一致。这些吡嗪衍生物掺入血管平滑肌膜的量也随着这些药物疏水性的增加而增加,即TMP < 3EP < TEP。我们的结果与以下观点一致,即这些吡嗪衍生物不仅与生物膜中的受体蛋白分子相互作用,还通过与脂质双层相互作用改变膜微粘度来调节这些受体特性。